AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2022
Nov 16, 2022
32883_dirs_2022-11-16_d7d114e2-7145-4228-b540-cd8486e01962.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2022-11-14
Reporting Person: Cittadine Andrew (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-11-14 | Common Stock | P | 6053 | $3 | Acquired | 14238 | Direct |
| 2022-11-15 | Common Stock | P | 10000 | $3.15 | Acquired | 24238 | Direct |